Actively Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Led by Capital Medical University · Updated on 2026-05-05
348
Participants Needed
13
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
CONDITIONS
Official Title
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Acute ischemic stroke caused by basilar artery occlusion
- Planned emergency endovascular treatment
- Time from stroke onset to groin puncture within 24 hours
- National Institutes of Health Stroke Scale (NIHSS) score of 10 or higher
- Posterior circulation Alberta Stroke Program Early CT score (pc-ASPECTS) of 6 or higher
- Signed informed consent from patient or legally authorized representative
You will not qualify if you...
- Presence of intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage
- Pre-stroke modified Rankin scale (mRS) score greater than 1
- Known allergy to tocilizumab or excipients
- Known allergy to iodinated contrast agents
- Difficulty completing endovascular treatment due to vascular tortuosity
- History of bleeding disorders, coagulation factor deficiencies, or thrombocytopenic diseases
- Systolic blood pressure 180 mmHg or higher or diastolic blood pressure 110 mmHg or higher despite control
- Neutrophil count less than 2 x 10^9 /L
- Platelet count less than 100 x 10^9 /L
- Blood glucose less than 2.8 mmol/L (50 mg/dL) or greater than 22.2 mmol/L (400 mg/dL)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than twice the upper limit of normal
- Recent or current serum creatinine more than twice the upper limit of normal or estimated glomerular filtration rate (eGFR) less than 60 mL/min
- Pregnant, lactating, or planning pregnancy within 90 days
- Severe mental disorders or inability to comply with consent and follow-up due to dementia
- Concurrent malignant tumors or severe systemic diseases with expected survival less than 90 days
- Presence of autoimmune diseases or use of immunosuppressive drugs
- Systemic infectious diseases
- Participation in another interventional clinical trial within 30 days before randomization or currently participating in another interventional trial
- Any condition judged by investigators to pose harm if study therapy is initiated
- Other conditions that may affect compliance or preclude participation as assessed by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Suzhou Municipal Hospital
Suzhou, Anhui, China, 234000
Actively Recruiting
2
Anyang People's Hospital
Anyang, Henan, China, 455000
Actively Recruiting
3
Nanyang Central Hospital
Nanyang, Henan, China, 473000
Actively Recruiting
4
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan, China, 453000
Actively Recruiting
5
People's Hospital of Xihua
Zhoukou, Henan, China, 466600
Actively Recruiting
6
People's Hospital of Linyi
Linyi, Shandong, China, 276000
Actively Recruiting
7
Zibo Central Hospital
Zibo, Shandong, China, 255000
Actively Recruiting
8
Xianyang First People's Hospital
Xianyang, Shanxi, China, 712000
Actively Recruiting
9
Yuncheng Central Hospital
Yuncheng, Shanxi, China, 044000
Actively Recruiting
10
Lishui Central Hospital
Lishui, Zhejiang, China, 323000
Actively Recruiting
11
Taizhou enze Hospital
Taizhou, Zhejiang, China, 318000
Actively Recruiting
12
People's Hospital of Yueqing
Yueqing, Zhejiang, China, 325600
Actively Recruiting
13
Capital Medical Univercity Xuanwu Hospital
Beijing, China, 100053
Actively Recruiting
Research Team
X
Xunming Ji
CONTACT
C
Chuanjie Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here